LENSAR, Inc. reported a net loss of $1.5 million, or $‑0.12 per share, for the quarter ended December 31 2025, a dramatic improvement from the $18.7 million loss ($‑1.61 per share) recorded in the same period a year earlier. Total revenue for the quarter fell 4% to $16.0 million, down $0.7 million from $16.7 million in Q4 2024. Full‑year recurring revenue rose 15% to $46.3 million, representing 79% of total revenue and underscoring the company’s shift toward a subscription‑style business model.
The company’s revenue miss relative to analyst expectations—$20.3 million forecast versus $16.0 million actual—was driven largely by a $2.6 million decline in system sales. The drop was attributed to distributor uncertainty surrounding the termination of the Alcon merger, which had been announced on March 18 2026. In contrast, procedure‑related revenue increased by $1.8 million, reflecting a 20% year‑over‑year rise in worldwide procedure volume and a 48% increase in the ALLY installed base to roughly 200 systems.
Operating expenses climbed 41% to $11.9 million, largely due to $3.5 million in acquisition‑related costs associated with the previously contemplated Alcon merger. Despite the higher operating costs, the net loss narrowed because the company’s recurring revenue grew and other operating items were controlled. Cash and investments at year‑end 2025 were $18.0 million, down from $22.5 million at year‑end 2024, but the balance remains sufficient to support ongoing capital needs.
President and CEO Nick Curtis emphasized the company’s resilience after the Alcon transaction news: "While the recent transaction‑related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry‑leading ALLY Robotic Laser Cataract System." He added that the company’s objective is to expand both its share of the laser‑assisted cataract surgery market and the broader robotic laser cataract market, noting that 79% of revenue in both the quarter and the full year came from recurring sources and that worldwide volume increased 22% in 2025 compared to 2024.
Investors responded positively to the results, citing the company’s strong recurring revenue growth and positive adjusted EBITDA as key factors that offset the missed analyst estimates for earnings per share and revenue. The market’s reaction reflects confidence in LENSAR’s strategic pivot to an independent, recurring‑revenue‑focused model following the termination of the Alcon merger.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.